Savara Inc. (FRA:YB4P)

Germany flag Germany · Delayed Price · Currency is EUR
4.780
-0.040 (-0.83%)
At close: Feb 20, 2026
Market Cap1.16B +97.0%
Revenue (ttm)n/a
Net Income-98.56M
EPS-0.46
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume50
Open4.780
Previous Close4.820
Day's Range4.780 - 4.780
52-Week Range1.660 - 5.900
Betan/a
RSI47.81
Earnings DateMar 6, 2026

About Savara

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania. [Read more]

Industry Pharmaceutical Preparations
Founded 2007
Employees 59
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol YB4P
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements